Advertisement

Document › Details
Faron Pharmaceuticals Oy. (1/4/21). "Press Release: Faron to Present at H.C. Wainwright BioConnect". Turku.
Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright BioConnect Conference that will be available on-demand starting Monday, January 11, 2021 at 6:00 a.m. ET.
An audio webcast of the presentations will be available in the "Investors" section on Faron's website at https://www.faron.com/investors
ENDS
For more information please contact:
Stern Investor Relations, Inc.
Julie Seidel, Naina Zaman
Phone: +(1)212 362 1200
Email: faron@sternir.com
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com
Record changed: 2021-01-05 |
Advertisement

More documents for Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON)
- [1] Faron Pharmaceuticals Oy. (2/5/18). "Press Release: Faron Establishes Second Traumakine Manufacturing Site". Turku....
- [2] Faron Pharmaceuticals Oy. (1/29/18). "Press Release: FDA Grants Fast Track Designation to Faron for Traumakine". Turku....
- [3] Faron Pharmaceuticals Oy. (3/1/17). "Press Release: Results of Placing and Subscription and Issue of Equity. Successful over-subscribed fundraising of £5.0 million through a Placing and Subscription [Not for United States, Australia, Canada, Japan, et al...
- [4] Faron Pharmaceuticals Oy. (2/28/17). "Press Release: Proposed Placing and Subscription to Raise Up to £5.0 Million [Not for United States, Australia, Canada, Japan, et al.]". Turku....
- [5] Faron Pharmaceuticals Oy. (11/17/15). "Press Release: Admission to AIM and First Day of Dealings. £10 million Fundraise to Progress Phase III Clinical Trial [Not for US, AU, CA, JP, ZA, IE or any other jurisdiction where unlawful]"....
- [6] Faron Pharmaceuticals Oy. (11/3/15). "Press Release: Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen". Turku....
- [7] Faron Pharmaceuticals Oy. (9/7/15). "Press Release: Intention to Float on AIM [not for US, AU, CA, JP, ZA, IE, et al.]". Turku....
- [8] Faron Pharmaceuticals Oy. (6/30/15). "Press Release: Faron Announces Collaboration with Turku PET Centre on Development of Novel Cancer Immunotherapy. Research Grant from Tekes to Fund Project". Turku....
- [9] Faron Pharmaceuticals Oy. (5/20/15). "Press Release: Faron Pharmaceuticals and China Medical System Holdings Enter into Strategic Agreement for the Development of Traumakine in China, Hong Kong, Macao and Taiwan. €5 Million Equity Investment Made by A&B...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top